A (n = 10) High sputum eosinophils, low red hue | B (n = 16) High sputum eosinophils, high red hue | C (n = 19) Low sputum eosinophils, low red hue | D (n = 58) Low sputum eosinophils, high red hue | p value | |
---|---|---|---|---|---|
Male, n (%) | 6 (60) | 13 (81.25) | 8 (42.1) | 42 (72.4) | 0.06 |
Age (years)* | 64 (3.3) | 67 (2.3) | 65 (2.4) | 70 (1.2) | 0.17 |
Body mass index (kg/m 2 ) | 26 (23–28) | 23 (20–26) | 25 (23–33) | 27 (23–30) | 0.09 |
Pack years smoked | 49 (36–58) | 47 (25–66) | 47 (34–60) | 48 (32–64) | 0.96 |
COPD duration (years) | 4.7 (2.9-10) | 8.5 (2.0-12) | 4.8 (2.1-6.7) | 4.9 (2.8-8.1) | 0.67 |
Exacerbations/yr | 0.7 (0–1.8) | 0.8 (0.1-1.4) | 1.2 (0–1.9) | 0.8 (0–1.6) | 0.51 |
ICS dose (BDP equivalent) (mcg/day) | 2000 (2000–2000) | 2000 (1000–2000) | 2000 (800–2000) | 1300 (800–2000) | 0.26 |
FEV 1 % predicted, (%) | 62 (43–75) | 44 (32–58) | 43 (26–67) | 55 (42–71) | 0.16 |
FEV 1 post bronchodilator (L) | 1.7 (1.2-1.9) | 1.1 (0.91-1.6) | 0.87 (0.73-1.6) | 1.4 (1–1.9) | 0.13 |
Post FEV 1 /FVC (%)* | 55 (5.4) | 50 (3.3) | 51 (4.2) | 53 (1.6) | 0.73 |
Reversibility, % | 3.5 (-7.1- 8) | 4.3 (1.5- 13) | 4.5 (-2.2- 14) | 1.5 (-4.4- 7.5) | 0.33 |
GOLD 1, n (%) | 1 (10) | 1 (6) | 5 (26) | 8 (14) | 0.38 |
GOLD 2, n (%) | 7 (70) | 6 (38) | 3 (16) | 26 (45) | 0.02 |
GOLD 3, n (%) | 0 (0) | 7 (44) | 4 (21) | 19 (33) | 0.02 |
GOLD 4, n (%) | 2 (20) | 2 (13) | 7 (37) | 5 (9) | 0.05 |
Sputum TCC ×10 6 /g | 1.2 (0.41-2) | 5.3 (2.1-8.2) | 1.6 (0.94-4.5) | 3.4 (1.7-7.6) | 0.002 |
Sputum neutrophils (%) | 45 (6.3) | 59 (6.1) | 66 (5.3) | 63 (2.7) | 0.07 |
Sputum eosinophils (%) | 9 (1.6-35) | 14 (4.9-24) | 0.5 (0.25-2.8) | 1 (0.3-2.1) | <0.0001 |
Sputum eosinophil AUC (%/yr) | 6.8 (4.2-11) | 5.9 (4.2-8.3) | 0.5 (0.2-1.6) | 0.78 (0.3-1.5) | <0.0001 |
% of red hue of macrophages | 2.3 (1.6-3.7) | 27 (11–35) | 3.4 (1.8-5.3) | 16 (9.1-27) | <0.0001 |
Blood neutrophils (×10 9 /L) | 5.1 (3.5-5.8) | 4.8 (3.8-5.9) | 5.9 (4.7-6.3) | 5.3 (3.9-6.1) | 0.13 |
Blood eosinophils (×10 9 /L) | 0.38 (0.24-0.46) | 0.41 (0.26-0.56) | 0.16 (0.09-0.25) | 0.18 (0.12-0.30) | <0.0001 |
CRP (mg/dl) | 5 (2.5-5.3) | 5 (<5-7) | 5 (2.5-11) | 5 (<5-11) | 0.08 |
Bacterial colonisation, n (%) | 1 (10) | 1 (6) | 8 (44) | 12 (21) | 0.04 |
CFU unit/ml** | 6.2 (5.8-6.6) | 6.1 (5.5-6.7) | 6.6 (6.3-7) | 6.2 (5.9-6.4) | 0.19 |
MRC Dyspnoea Scale | 3 (2–4) | 3 (2–4) | 3 (2.5-4.5) | 3 (2–4) | 0.82 |
SGRQ symptoms | 61 (37–80) | 65 (29–82) | 73 (55–84) | 62 (50–77) | 0.34 |
SGRQ activity | 76 (35–89) | 73 (48–85) | 73 (59–92) | 67 (48–86) | 0.55 |
SGRQ impacts | 31 (16–58) | 44 (20–66) | 42 (29–47) | 32 (23–51) | 0.86 |
SGRQ total score | 50 (30–67) | 55 (32–71) | 57 (49–65) | 50 (37–65) | 0.75 |
CRQ emotional functioning | 4.7 (3.4-5.8) | 4.3 (3.9-6.3) | 4.4 (3.9-5.3) | 4.5 (3.6-5.6) | 0.83 |
CRQ fatigue | 3.8 (3.4-4.9) | 3.3 (2.8-5.3) | 4.0 (2.3-4.8) | 3.5 (2.5-4.8) | 0.51 |
CRQ dyspnoea | 4 (3–4.9) | 3.4 (2.6-4.2) | 3 (2.2-4) | 3.4 (2.2-4.4) | 0.28 |
CRQ mastery | 5.4 (4.4-6.4) | 5.0 (3.8-6.3) | 4.0 (3.8-5.5) | 5.3 (3.7-6.1) | 0.63 |
CRQ total score | 4.4 (3.7-5.2) | 4.1 (3.4-4.9) | 4.0 (3.1-4.6) | 4.2 (3.1-5.0) | 0.50 |
VAS cough (mm) | 17 (10–43) | 35 (14–52) | 47 (18–62) | 34 (13–54) | 0.23 |
VAS dyspnoea (mm) | 40 (4.8-59) | 43 (32–81) | 51 (35–62) | 46 (22–65) | 0.40 |
VAS sputum production (mm) | 15 (4.5-42) | 36 (19–52) | 38 (93–66) | 28 (12–63) | 0.40 |
VAS sputum purulence (mm) | 14 (2–61) | 17 (1–45) | 38 (15–62) | 21 (9.5-41) | 0.41 |